ArticleScience translational medicine2020
The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas.
Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Genetic Variants Impacting Angiogenesis Signaling Pathways in Glioblastoma Multiforme: A Systematic Review of Mutations and Polymorphisms.Current molecular medicine · 2024Pooled it
- Fused inverse-normal method for integrated differential expression analysis of RNA-seq data.BMC bioinformatics · 2022Pooled it
- Peptide-mediated inhibition of aberrant chaperone-mediated autophagy in pericytes prevents glioblastoma progression through MAPT/tau secretion.Autophagy · 2026Article
- The cancer Alzheimer's disease paradox.npj aging · 2026Article
- Application of a multimodal MRI model integrating radiomics and habitat features for predicting glioma pathology and prognosis.BMC medical imaging · 2026Article
- Review
- Angiogenesis and Resistance Mechanisms in Glioblastoma: Targeting Alternative Vascularization Pathways to Overcome Therapy Resistance.Current pharmaceutical design · 2026Review
- HumaneLife · 2025Article
- Tau impedes glioma progression by enhancing fatty acid β-oxidation-induced cellular senescence.Zoological research · 2025Article
- A Narrative Review of Theranostics in Neuro-Oncology: Advancing Brain Tumor Diagnosis and Treatment Through Nuclear Medicine and Artificial Intelligence.International journal of molecular sciences · 2025Review
- High Tau expression correlates with reduced invasion and prolonged survival in Ewing sarcoma.Cell death discovery · 2025Article
- Preoperative prediction of IDH genotypes and prognosis in adult-type diffuse gliomas: intratumor heterogeneity habitat analysis using dynamic contrast-enhanced MRI and diffusion-weighted imaging.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Cancer metabolism rewiring and chromatin methylation: a vulnerable epi-metabolic link.Frontiers in epigenetics and epigenomics · 2025Article
- Immuno-oncological interactions between meningeal lymphatics and glioblastoma: from mechanisms to therapies.Theranostics · 2025Review
- S100A proteins show a spatial distribution of inflammation associated with the glioblastoma microenvironment architecture.Theranostics · 2025Article
- Novel cuprotosis-related gene signature: a prognostic indicator and regulator of the glioma immune microenvironment.Translational cancer research · 2024Article
- Therapeutic Contribution of Tau-Binding Thiazoloflavonoid Hybrid Derivatives Against Glioblastoma Using Pharmacological Approach in 3D Spheroids.International journal of molecular sciences · 2024Article
- Review
- A triad between sex, necrosis, and inflammation shapes glioblastoma outcomes.Neuro-oncology · 2024Article
- EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.Neuro-oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 2 countries.
Funding
Abstract
Gliomas that express the mutated isoforms of isocitrate dehydrogenase 1/2 (IDH1/2) have better prognosis than wild-type (wt) IDH1/2 gliomas. However, how these mutant (mut) proteins affect the tumor microenvironment is still a pending question. Here, we describe that the transcription of microtubule-associated protein TAU (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.